Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant intravesical mitomycin C for primary treatment-naive bladder tumors
2021-003751-42Phase 3Terminated
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mitomycin c in bladder cancer (2 arms), sponsored by Humanitas Research Hospital. Primary endpoint: Recurrence-free complete response rate at 3, 6, 12, and 24 months. Started Oct 2021; status: terminated.
02
Drugs
mitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2021-003751-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003751-42.